AstraZeneca Pharma India gets DCGI nod to market cancer drug in India

New Delhi: Drug firm AstraZeneca Pharma India today said it has received permission from the Drug Controller General of India (DCGI) to import and market olaparib tablets used for the treatment of ovarian and breast cancer. The permission from the DCGI is for olaparib (Lynparza) tablets in the strengths of 100 mg and 150 mg, AstraZeneca Pharma India said in a BSE filing.

The tablets are a patented product of the AstraZeneca group, it added.

“The import and market permission for olaparib is a significant milestone for women in India living with platinum-sensitive relapsed ovarian cancer and BRCA-mutated HER-2 negative metastatic breast cancer, which has historically been difficulty-to-treat diseases,” AstraZeneca Pharma India MD Gagan Singh said.

Shares of AstraZeneca Pharma India today closed at Rs 1,710.30 per scrip on BSE, up 1.59 per cent from their previous close.

  • Related Posts

    Eli Lilly launches cancer drug Tanstrive in India

    New Delhi: Eli Lilly and Company India on Thursday announced the launch of its cancer treatment drug Tanstrive in India. The launch follows marketing authorisation from the Central Drugs Standard Control Organisation…

    Centre eases BIS quality compliance with new risk-based framework for manufacturers

    The Centre has introduced a risk-based compliance mechanism to ease industry compliance with Quality Control Orders (QCOs), allowing eligible manufacturers to follow a simplified certification route while maintaining product quality…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Eli Lilly launches cancer drug Tanstrive in India

    Eli Lilly launches cancer drug Tanstrive in India

    Sir Ganga Ram Hospital excels in Medical Research among Private Hospitals

    Sir Ganga Ram Hospital excels in Medical Research among Private Hospitals

    Centre eases BIS quality compliance with new risk-based framework for manufacturers

    Centre eases BIS quality compliance with new risk-based framework for manufacturers

    SS Innovations International aces Race beating Global Giants in Surgical Robotics

    SS Innovations International aces Race beating Global Giants in Surgical Robotics

    ‘SHE’ comes all the Way from Calcutta to Delhi to Care for Women’s Fertility

    ‘SHE’ comes all the Way from Calcutta to Delhi to Care for Women’s Fertility

    India curbs supply of IVF consumables to unregistered clinics

    India curbs supply of IVF consumables to unregistered clinics